TH104

About Tharimmune

Tharimmune is pioneering a transmucosal drug delivery platform designed to enhance the bioavailability and tolerability of challenging therapeutics. Its most advanced program, TH104, is in Phase 2 development for pruritus associated with PBC, a condition with no FDA-approved therapies. The company's strategy involves repurposing established drug molecules with its buccal film technology to create new, patent-protected treatments for serious conditions, aiming to accelerate development timelines and reduce risk.

Therapeutic Areas